×
News Home

Does Alnylam Pharmaceuticals, Inc. (ALNY) Have What it Takes to be in Your Portfolio Thursday?

Thursday, October 28, 2021 10:07 AM | InvestorsObserver Analysts
Does Alnylam Pharmaceuticals, Inc. (ALNY) Have What it Takes to be in Your Portfolio Thursday?

A rating of 79 puts Alnylam Pharmaceuticals, Inc. (ALNY) near the top of the Biotechnology industry according to InvestorsObserver. Alnylam Pharmaceuticals, Inc.'s score of 79 means it scores higher than 79% of stocks in the industry. Alnylam Pharmaceuticals, Inc. also received an overall rating of 52, putting it above 52% of all stocks. Biotechnology is ranked 86 out of the 148 industries.

Overall Score - 52
ALNY has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on ALNY!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes

InvestorsObserver

’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Alnylam Pharmaceuticals, Inc. Stock Today?

Alnylam Pharmaceuticals, Inc. (ALNY) stock has fallen -14.82% while the S&P 500 is higher by 0.61% as of 10:06 AM on Thursday, Oct 28. ALNY has fallen -$28.32 from the previous closing price of $191.16 on volume of 549,487 shares. Over the past year the S&P 500 has risen 40.00% while ALNY is higher by 30.40%. ALNY lost -$7.60 per share the over the last 12 months. Click Here to get the full Stock Report for Alnylam Pharmaceuticals, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App